Tag Archives: Pfizer Inc.

Icahn’s latest target, Bristol-Myers, may play hard-to-get; unless Pfizer comes a courting

The News: Activist investor Carl Icahn just announced his latest target: Bristol-Myers Squibb Co., reports the Wall Street Journal. Bristol-Myers has been the focus of several activist investors in recent… Read more »

Pfizer stumbles to 4Q profit after rough year for Prevnar; what happened to industry leadership role?

News: Pfizer Inc.’s (New York City) key pneumococcal vaccine, Prevnar, whose sales soared through 2015, stumbled in fourth-quarter results (pdf) released last week. The blockbuster inoculation fell significantly short of Street… Read more »

Japan’s Takeda leads off 2017 M&A season with gutsy deal to buy US cancer specialist Ariad for $5.2 billion; it’s expensive, but probably worth it

Japan’s Takeda Pharmaceutical Co. Ltd. agreed to acquire Ariad Pharmaceuticals Inc. (Cambridge MA) for $24 per share in cash, or an enterprise value of approximately $5.2 billion, boosting its oncology… Read more »

Johnson & Johnson eyeing Actelion; who wouldn’t with a “pro-biotech” Trump administration?

Johnson & Johnson (New Brunswick NJ) said Friday (November 11, 2016) it is in “preliminary discussions” with Swiss drug company Actelion Pharmaceuticals Ltd. (Basel CHE), a deal that would help the… Read more »

Trump win sends pharma stocks up, while hospitals plunge; fate of Obamacare far from clear

Pharmaceutical stocks and bonds were among the day’s biggest winners Wednesday (November 9, 2016) as the sweeping Republican victory in US elections eased concern that price controls might be imposed… Read more »

Pfizer misses 3Q views but gets nod for Prevnar from China; Mao would scowl, but not Xi

More than a year after pulling its vaccines out of one of the world’s most challenging but lucrative drug markets, Pfizer has moved back into China with a thumbs up for top-selling… Read more »

Johnson & Johnson Tumbles as Pfizer Set to Launch Remicade Biosimilar; Solid 3rd Quarter Doesn’t Quell Market’s Overreaction

Thriving pharmaceutical sales drove stellar quarterly results for Johnson & Johnson (New Brunswick NJ), but the company’s shares fell 3% so far this week on worries that its smash hit,… Read more »

Bristol Myers Clobbered as Cancer Drug Disappoints; Rival Merck Unanimous Winner at Medical Conference

New data are likely to prompt doctors to abandon Bristol-Myers Squibb Co.’s (New York City) immunotherapy Opdivo in favor of Merck & Co.’s (Kenilworth NJ) rival Keytruda in a large… Read more »

Glaxo Settles Bribery Charges with SEC for $20 Million; Cozy Relation of Pharma with Docs a Thing of the Past?

GlaxoSmithKline PLC (London) will pay $20 million to settle civil charges that it masked bribes to foreign officials in China by disguising them as legitimate travel, entertainment and marketing expenses,… Read more »

Tenet to Pay $553 Million to Settle Kickback Allegations; Culture of Corruption Dates Back Decades

Tenet Healthcare Corp. (Dallas TX) and two of its Atlanta subsidiaries have agreed to pay more than $513 million to resolve criminal and civil claims accusing the chain of paying… Read more »